Henry Schein Earnings Call Transcripts
Fiscal Year 2026
-
Strong Q4 and 2025 results were driven by market share gains in dental equipment and merchandise, successful promotions, and digital innovation. Leadership transition and KKR's involvement bring fresh perspectives, while cost savings and share buybacks support growth and profitability.
-
A new CEO brings operational expertise and a fresh outlook, while the company shifts to offensive growth strategies, especially in dental equipment and specialty products. AI-driven technology and a structural value creation plan target efficiency and margin gains, with at-home medical care as a key growth area.
-
Leadership transition to Fred Lowery is set to drive the BOLD+1 strategy, with strong momentum in market share gains and a $200M+ value creation plan underway. Investments in technology, innovation, and sales force expansion support growth, while financial trends remain positive.
Fiscal Year 2025
-
Fourth quarter saw record sales growth and strong earnings, driven by robust performance in equipment, specialty, and technology segments. 2026 guidance projects continued growth, with earnings weighted to the year's second half as value creation initiatives ramp up.
-
Leadership transition is underway with a new CEO expected soon, while the company continues to drive growth through high-margin products, value creation initiatives, and digital solutions. The dental market remains stable, and strategic focus on integration and efficiency positions the business for sustained profitability.
-
Leadership transition is underway with a new CEO to be named by year-end. The business has rebounded from a cyber incident, is gaining market share, and is driving margin growth through value-creation initiatives, technology investments, and an expanded product portfolio.
-
International dental and equipment markets are outperforming the U.S., but U.S. specialty products are gaining momentum. A $200 million cost savings initiative is underway, with benefits expected from 2026. Technology and e-commerce platforms are driving growth, and the medical segment is stabilizing at mid-single digit growth.
-
Third quarter saw accelerating sales, strong market share gains, and improved non-GAAP margins. 2025 guidance was raised, with EPS now expected at $4.88–$4.96 and sales growth of 3%–4%. Key initiatives include a $200M operating income improvement plan and expanded share repurchases.
-
Stable dental patient traffic and lower interest rates are supporting equipment and practice build-outs, while targeted promotions and new sales hires are driving customer engagement. Cost optimization projects and a flexible capital deployment strategy are expected to support future EPS growth. Specialty, medical, and technology segments show mixed but generally positive trends.
-
High growth, high margin products now make up nearly 60% of operating income, and value creation projects are underway to optimize both gross profit and operational efficiency. Dental markets remain stable with signs of recovery in Europe, while innovation and technology adoption are seen as key future growth drivers.
-
Q2 results initially disappointed but investor sentiment improved as guidance and growth initiatives were clarified. Revenue and EPS are expected to ramp in H2, supported by equipment recovery, technology momentum, and cost optimization projects. E-commerce and SaaS transitions, targeted M&A, and restructuring are driving long-term growth.
-
Q2 sales grew 3.3% year-over-year to $3.2B, with strong performance in medical, specialty, and technology segments, though U.S. margins were pressured by lower glove pricing and targeted promotions. 2025 guidance is maintained, with earnings expected to be weighted to the second half and value creation initiatives underway.
-
Management outlined a strategy to grow high-margin specialty and digital businesses, targeting 50% of income from these areas by 2027. Market trends are stable, with a shift to SaaS and recurring revenue. KKR's investment is expected to enhance operational efficiency and margin management.
-
Momentum improved after a slow January, with stable dental and medical markets and strong growth in European implants and medical home solutions. Key initiatives include expanding specialty product sales, launching global e-commerce, and a restructuring plan targeting $75M-$100M in annual savings. Strategic DSO partnerships and KKR's involvement should drive further growth.
-
Dental demand rebounded after a slow January, with new office build-outs and DSOs driving growth. 2025 guidance is steady, supported by cost savings, digital expansion, and new product launches. Implant growth is strong in Europe, while US focus shifts to value implants and home medical solutions.
-
First quarter 2025 saw stable sales and margin improvement, with 2% constant currency growth excluding PPE/COVID kits and strong performance in specialty, technology, and home solutions. Guidance for 2025 is maintained, with tariff and FX risks expected to be mitigated.
-
Dental and medical markets are stabilizing post-pandemic, with digital equipment and value-added services driving growth. Strategic acquisitions and KKR's investment are expanding specialty offerings and operational efficiency, while innovation in diagnostics and treatment is enhancing patient care.
-
The event highlighted a strategic shift toward high-margin, high-growth products and digital solutions, with over half of profits now from owned and private label brands. Recovery from a cyber incident and ongoing restructuring are expected to support margin and earnings growth through 2025.
Fiscal Year 2024
-
Fourth quarter 2024 saw stable end markets, strong growth in high-margin businesses, and improved margins. 2025 guidance anticipates modest sales and EPS growth, with restructuring and KKR’s investment supporting future performance. Segment reporting was updated for greater transparency.
-
The event highlighted expansion in the implant market, digital transformation with a new e-commerce platform, and ongoing cost restructuring. Diversification in medical and home solutions, supply chain adjustments, and a focus on synergistic M&A were emphasized as key growth drivers.
-
Leadership highlighted strong business integration, ongoing restructuring for efficiency, and a shift toward value and digital solutions. Private label growth, digital platforms, and a focus on leveraging customer relationships are central to the next strategic phase.
-
The dental market is stable with a shift to lower-priced products, supporting strong profitability despite softer sales. Recovery from the 2023 cyber incident continues, with market share gains expected to benefit 2025. Strategic cost savings and leadership succession are on track.
-
Dental and specialty businesses are seeing stable volumes, with a shift toward private label and value brands boosting margins. Specialty and implant segments are driving growth, supported by recent acquisitions and restructuring initiatives targeting significant cost savings by 2025.
-
Q3 2024 results exceeded expectations, with strong performance in high-margin businesses and continued market share recovery post-cyber incident. Guidance for 2024 non-GAAP EPS was raised, and restructuring is on track to deliver significant cost savings.
-
Dental and medical markets are stable with some regional and product-specific challenges, but new product launches and technology innovation are expected to drive growth. Recovery from cyber incidents is progressing, and restructuring efforts should yield cost savings and improved performance by 2025.
-
Dental and medical markets are stable, with growth driven by specialty, technology, and home health segments. New product launches, acquisitions, and restructuring are expected to boost revenue and profitability, while the transition to SaaS and e-commerce investments support long-term growth.
-
Q2 2024 saw solid cash flow and margin expansion, but sales growth slowed due to a sluggish recovery from last year’s cyber incident and a challenging economic environment. Guidance for 2024 was lowered, with restructuring and increased share buybacks planned to drive future efficiency and shareholder value.
-
Dental market recovery is underway with stable patient traffic and capacity constraints, while digitalization and specialty products drive growth. High-margin businesses now contribute half of operating income, and M&A will focus on integration and minority buyouts this year.
-
First quarter results showed stabilization after a cyber incident, with specialty and software businesses driving profit growth. Digital equipment and cloud-based solutions are expanding, and new products are expected to boost performance in the year's second half.